CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology and inflammation.
Our premier Translational Platforms for cancer and inflammation helps our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. We are a global company with facilities across the world in the United States, United Kingdom, Netherlands, China, and Taiwan.
Our premier Translational Platforms for cancer and inflammation helps our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. We are a global company with facilities across the world in the United States, United Kingdom, Netherlands, China, and Taiwan.
Location: United States, California, San Diego
Employees: 201-500
Phone: +1 855-827-6968
Total raised: $55.35M
Founded date: 2006
Investors 5
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | Qiming Ven... | qimingvent... |
| - | Acorn Camp... | acorncampu... |
| - | Acorn Paci... | acornpacif... |
| - | Qiming Ven... | qimingvc.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.05.2014 | Series D | $26.55M | - |
| 04.05.2011 | Series C | $28.8M | - |
Mentions in press and media 24
| Date | Title | Description |
| 03.07.2026 | Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence | CAMBRIDGE, Mass., July 3, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the ap... |
| 16.12.2024 | Enhance Early Biomarker Discovery: Translating In Vitro and In Vivo Multi-Omics Oncology Data, Upcoming Webinar Hosted by Xtalks | www.crownbio.com In this free webinar, learn how to integrate multi-omics data from diverse oncology models to identify early biomarkers and de-risk drug development. Attendees will learn strategies for translating complex in vitro and in v... |
| 04.11.2024 | Targeted Therapies: The Role of Large Molecules, Biologics and ADCs, Upcoming Webinar Hosted by Xtalks | www.crownbio.com In this free webinar, learn how to enhance biologics and antibody-drug conjugate (ADC) development programs with cutting-edge technologies and transform the development of targeted therapies. The featured speakers will disc... |
| 16.10.2024 | Antibody-Drug Conjugates: Bridging Precision and Potency in Oncology, Upcoming Webinar Hosted by Xtalks | www.crownbio.com In this free webinar, learn how leveraging the industry's largest collection of in vivo PDX and in vitro 3D organoids can revolutionize preclinical antibody-drug conjugate evaluation and overcome resistance challenges. Atte... |
| 01.10.2024 | Four-Step Preclinical Strategy to Tackle Cancer Drug Resistance, Upcoming Webinar Hosted by Xtalks | www.crownbio.com In this free webinar, learn about the complex mechanisms of cancer drug resistance and how a four-step preclinical strategy can help identify effective tools to overcome it. Attendees will learn key models and approaches fo... |
| 23.04.2024 | HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML) | SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows st... |
| 13.11.2023 | PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE | PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal fa... |
| 08.10.2021 | JSR : Crown Bioscience Launches ‘3D Ex Vivo Patient Tissue Platform' to Improve Predictability of Immuno-Oncology Drug Candidates | October 8, 2021 - Crown Bioscience, a JSR Life Sciences Company, announced the launch of its '3D Ex Vivo Patient Tissue Platform' to improve predictability of immuno-oncology drug candidates. For more information on Crown Bioscience's 3D Ex... |
| 14.06.2019 | Crown Bioscience announces four new preclinical NASH models in development | Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research today announced four new preclinical translational... |
| 14.06.2019 | Crown Bioscience announces four new preclinical NASH models in development | Crown Bioscience announces four new preclinical NASH models in development 14-06-2019 Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovasc... |
Show more